title: Butyrylcholinesterase K variants increase the risk of coronary artery disease in the population of western Iran.
abstract: The conflicting results of several studies suggest that there is an association between the butyrylcholinesterase-K variant (BCHE-K, G1615A/Ala539Thr) and the risk of developing coronary artery disease (CAD) in diabetes and non-diabetic subjects. The objective of this study was to determine whether the presence of the BCHE-K variant exacerbates the risk of CAD in patients from western Iran with and without type 2 diabetes mellitus (T2DM). This case-control study comprised 464 subjects undergoing their first coronary angiography. They were matched and randomly assigned into four groups: CAD+T2DM+ (CAD/T2DM), CAD+DM(-) (CAD/ND), CAD(-)DM+ (T2DM/NCAD) and CAD(-)DM(-)(control). The BCHE-K variant was detected by PCR-RFLP. The BCHE-K allele frequency in CAD patients with and without T2DM [total CAD (TCAD)] and separately for each group (CAD/T2DM and CAD/ND) was significantly higher than in the control group (21.1 % versus 13.3 % (p = 0.001), 22.4 % versus 13.3 % (p = 0.001) and 19.7 % versus 13.3 % (p = 0.015), respectively). The odds ratios (ORs) for the BCHE-K heterozygous and homozygous variants in TCAD subjects were 1.65 (95 % CI 1.17-2.3; p = 0.004) and 4.3 (1.05-19.4; p = 0.048); for CAD/T2DM individuals 1.76 (1.2-2.6; p = 0.004) and 4.73 (0.96-23.3; p = 0.052); and for CAD/ND patients 1.53 (1.05-2.3; p = 0.029) and 3.88 (0.8-19.7; p = 0.7), respectively. The OR of the BCHE-K allele was found to be 1.74 (1.1-2.4; p = 0.001) in TCAD subjects, 1.87 (1.12-1.48; p = 0.001) in the CAD/T2DM group and 1.59 (1.04-1.4; p = 0.016) in CAD/ND subjects. These data suggest that the BCHE-K allele increases the risk of CAD in the population (with and without DM) in western parts of Iran, and its presence intensifies the risk of CAD in T2DM. The fact that the BCHE-K allele, even in the heterozygous form, exacerbates the risk of CAD in this population, suggests that a specific therapeutic intervention should be considered for this particular group of patients.
authors.affiliation: Department of Clinical Biochemistry, Kermanshah University of Medical Sciences, Kermanshah, Iran. vaisira@yahoo.com
authors.forename: A
authors.initials: A
authors.lastname: Vaisi-Raygani
authors.forename: Z
authors.initials: Z
authors.lastname: Rahimi
authors.forename: H
authors.initials: H
authors.lastname: Entezami
authors.forename: H
authors.initials: H
authors.lastname: Kharrazi
authors.forename: F
authors.initials: F
authors.lastname: Bahrhemand
authors.forename: H
authors.initials: H
authors.lastname: Tavilani
authors.forename: M
authors.initials: M
authors.lastname: Rezaei
authors.forename: A
authors.initials: A
authors.lastname: Kiani
authors.forename: B
authors.initials: B
authors.lastname: Nomanpour
authors.forename: T
authors.initials: T
authors.lastname: Pourmotabbed
mesh_terms: D001483:Base Sequence; D002091:Butyrylcholinesterase / Q000235:genetics / Q000378:metabolism*; D003324:Coronary Artery Disease / Q000201:enzymology / Q000453:epidemiology*; D017931:DNA Primers; D005838:Genotype; D006801:Humans; D007492:Iran / Q000453:epidemiology; D016133:Polymerase Chain Reaction; D012307:Risk Factors
chemical_list: D017931:DNA Primers; D002091:Butyrylcholinesterase